{"id":"W3093923068","doi":"10.1016/s1470-2045(20)30436-8","title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":745,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme","keywords":"Axitinib; Medicine; Sunitinib; Renal cell carcinoma; Pembrolizumab; Interim analysis; Internal medicine; Clinical endpoint; Oncology; Population; Kidney cancer; Clinical trial; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1632971678821501,"score_gpt":0.3918027228166789,"score_spread":0.2285055549345288,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}